Actualités

Centene stock has surged over the past year, yet the current checks still suggest it leans on the cheap side, so investors are weighing how much of the recent optimism is already reflected in the price. Centene has returned 145.2% over the past year, which puts a spotlight on whether the recent share price strength is outpacing the underlying fundamentals. Raised expectations for future revenue and earnings, together with a plan to redeem part of its debt, can support the case for improved...

BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.

SNDR, CNC, and TAL it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 13, 2026.

CNC and BEN have surged 61.7% and 40.3%, respectively, year to date, while disciplined execution and attractive valuations support their outlook.

Hotchkis & Wiley, an investment management company, released its second-quarter 2026 investor letter for the “Hotchkis & Wiley Mid-Cap Value Fund.” A copy of the letter can be downloaded here. Equity markets posted strong returns in the second quarter of 2026, with the Russell Midcap Index rising 13.8% and the Russell Midcap Value Index returning 13.4%, […]

Centene joins three other GARP picks with discounted PEG ratios and solid long-term growth potential. See what puts these stocks on the list.

MTD beats Q2 earnings estimates as strong China and emerging-market sales fuel growth, while the company raises its 2026 sales and earnings outlook.

UNH's diversified platform, AI expansion and Optum momentum strengthen its long-term outlook, making it the stronger managed care pick over CNC.

Cigna delivers an earnings and revenue beat as Cigna Healthcare fuels growth, while the company raises its 2026 EPS outlook despite higher pharmacy costs.

TRV, NMR and CNC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 30, 2026.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

UNH's improving cost control, lower medical costs and higher 2026 outlook are boosting confidence as its profitability recovery gains traction.

Centene (CNC) delivered a stronger-than-expected Q2, but investor attention shifted to management's

Centene's improved medical-cost ratio supported substantially higher annual earnings and revenue expectations.

CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.

S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. CNC stock initially moved higher, but shares reversed sharply lower as the company discussed its outlook, including slightly higher Medicaid attrition and a more costly covered population in the second half of 2026. Centene posted Q2 earnings of $2.51 a share, crushing forecasts of $1.09 by $1.42 a share.

Centene Corporation (NYSE:CNC) reported better-than-expected second-quarter results on Tuesday, delivering earnings and revenue that comfortably exceeded Wall Street forecasts as improved performance across its Medicare and Commercial businesses supported a stronger full-year outlook. Shares of the health insurer rose 3.

CNC reports Q2 results July 28 as investors weigh improving profitability against membership declines and revenue pressure ahead of earnings.

Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.

UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.

The healthcare giant posts better-than-expected second-quarter earnings and hikes its full-year guidance.

CNC stock's 66% rally reflects improving margins, stronger cash flow and renewed earnings growth, but can the turnaround keep gaining momentum?

While Wall Street fixated on a gloomy forecast, the company was making a painful but telling choice that hinted at the turnaround to come.

Baird said the outcomes from the final 2025 healthcare exchange risk adjustment transfers support Centene’s prior Q4 commentary and align directionally with Oscar’s comments at a June investor conference.

CLS, CBOE, and CNC it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 29, 2026.

CBOE, CNC and CRDO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 25th, 2026.

CBOE, CNC and CRDO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 23rd, 2026.

Centene (CNC) has drawn fresh attention after launching a voluntary buyout program for most employees, in response to a substantial drop in health plan membership tied to expiring federal pandemic subsidies and higher consumer costs. See our latest analysis for Centene. At a share price of $61.02, Centene has seen a 77.38% 90 day share price return and a 46.05% year to date share price return, while the 5 year total shareholder return has declined 17.43%. This suggests strong recent momentum...

In recent days, Centene offered voluntary buyouts to most of its roughly 61,000 employees after experiencing significant membership declines in its Affordable Care Act and Medicaid health plans. This workforce move, coupled with broader cost-cutting efforts, underscores how shifts in government-backed coverage can quickly reshape a major insurer’s operating footprint and priorities. We’ll now examine how offering broad voluntary employee buyouts to cut costs may influence Centene’s...

Centene (NYSE:CNC) has launched a wide-scale voluntary separation program, offering buyouts to most of its roughly 61,000 employees. The move comes as the company faces sharp health plan membership declines, particularly in its Medicaid and Affordable Care Act businesses. Centene has indicated that layoffs could follow if voluntary exits do not meet internal targets. The program is unfolding against a backdrop of major workforce restructuring and evolving regulatory and eligibility...